Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Considered healthy after undergoing a clinical evaluation;~* Agree freely and sign the Recruitment and Informed Consent Term, after all the content of the protocol was clear before any procedure;~* Present the body mass index greater than 19 and less than 30.~Exclusion Criteria:~* Results of laboratory tests outside the range considered normal, unless they were considered clinically irrelevant;~* Allergic to lamivudine or any other drug;~* Positive outcome of the pre-admission pregnancy test;~* Regular medication within four (4) weeks prior to the start of the study or use of any medication to present interaction with lamivudine one week before the start of the study;~* Use abusive alcoholic beverage;~* Use of illicit drugs and tobacco;~* History of liver disease, renal, pulmonary, gastrointestinal, epileptic, hematologic or psychiatric; hypo- or hypertension of any cause that required pharmacological treatment; myocardial infarction, angina and / or heart failure;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Period 1 (Type: ACTIVE_COMPARATOR): Epivir ® tablet 150-mg single dose (drug reference)
- Period 2 (Type: EXPERIMENTAL): Lamivudine 150-mg tablet single dose (drug test)

Based on this trial design, predict the completion outcome and termination type (if applicable).